| abstract |
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind IRTA-5 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Bispecific molecules of immunoconjugates and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-5, as well as methods for treating various malignancies of B cells, including non-Hodgkin's lymphoma. |